Physician profile
Gregory M Thomas
NPI 1386608412
$4,580.03
in general payments reported to CMS, 2019-2025
38 companies · $31.20 in 2025
The $31.20 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $445 · 2021: $988 · 2022: $1,044 · 2023: $1,137 · 2024: $45.18 · 2025: $31.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $706.29 | 2020-2024 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $600.68 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Amgen INC. | $444.15 | 2019-2023 | Tezspire, Prolia, Evenity |
| Pfizer INC. | $396.83 | 2019-2023 | |
| Novo Nordisk INC | $330.53 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $238.72 | 2019-2023 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $237.12 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $161.49 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.26 | 2020-2022 | |
| Amarin Pharma, INC. | $139.94 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $138.12 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $131.52 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $100.49 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.99 | 2019-2025 | |
| Astellas Pharma US INC | $82.74 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $72.79 | 2019-2022 | |
| Allergan, INC. | $63.72 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $55.09 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.96 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.37 | 2023 | Xifaxan |
| Si-Bone, INC. | $33.57 | 2021 | |
| Sumitomo Pharma America, INC. | $32.65 | 2023 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.66 | 2022-2023 | Tradjenta |
| Abbott Laboratories | $29.83 | 2022 | |
| Dexcom, INC. | $24.29 | 2021 | |
| Axsome Therapeutics, INC. | $22.39 | 2023 | Auvelity |
| Genentech USA, INC. | $17.05 | 2021 | |
| Acadia Pharmaceuticals INC | $16.70 | 2022 | |
| Shire North American Group INC | $15.89 | 2019 | |
| Smith+Nephew, INC. | $15.22 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.93 | 2021 | |
| Eisai INC. | $14.67 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.04 | 2020 | |
| Zyla Life Sciences, INC. | $12.29 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.86 | 2021 | |
| Ironwood Pharmaceuticals, INC | $11.67 | 2020 | |
| Bausch Health US, LLC | $11.33 | 2021 | |
| Mylan Specialty L.P. | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.